Physician profile
Allison E Arch
NPI 1043509953
$2,981.45
in general payments reported to CMS, 2019-2025
20 companies · $1,321 in 2025
The $1,321 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2021: $22.11 · 2022: $14.38 · 2023: $313 · 2024: $1,172 · 2025: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,792 · Education: $13.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,792.09 |
| Education | $13.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.05 | 2022-2025 | Botox, Ubrelvy |
| Ucb, INC. | $708.18 | 2023-2025 | Zilbrysq, Rystiggo, Briviact |
| Pfizer INC. | $357.33 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $283.83 | 2023-2025 | |
| Biogen, INC. | $145.58 | 2019-2024 | Leqembi |
| Lilly USA, LLC | $99.24 | 2024-2025 | Emgality, Kisunla |
| Genentech USA, INC. | $97.93 | 2024 | Ocrevus, Ocrevus Zunovo |
| Scilex Pharmaceuticals INC. | $47.13 | 2024 | |
| Alexion Pharmaceuticals, INC. | $34.96 | 2025 | Ultomiris |
| Lundbeck LLC | $32.85 | 2024 | Vyepti |
| Argenx US, INC. | $32.39 | 2023 | Vyvgart Hytrulo |
| Genentech, INC. | $26.92 | 2025 | Ocrevus |
| Microtransponder, INC. | $26.76 | 2024 | |
| Cycle Pharmaceuticals INC | $26.53 | 2025 | Tascenso Odt, Bafiertam |
| Insightec,INC | $25.12 | 2025 | Exablate |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.11 | 2021 | |
| Medtronic Vascular, INC. | $20.73 | 2019 | |
| Eisai INC. | $18.12 | 2024 | |
| Tanabe Pharma America, INC. | $14.58 | 2024 | |
| Amgen INC. | $13.11 | 2024 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Arch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.